共 28 个 OTC 专论产品
| 序号 | NDC编码 | 商品名 | 剂型 | 上市日期 | 专论编号 |
|---|---|---|---|---|---|
| 1 | 80513-611-02 | Sodium Bicarbonate 10 GR (650 MG) | TABLET | 2025-09-01 | M001 |
| 2 | 80513-112-01 | Gas Relief | CAPSULE, LIQUID FILLED | 2024-08-30 | M002 |
| 3 | 80513-111-12 | Gas Relief | CAPSULE, LIQUID FILLED | 2024-08-30 | M002 |
| 4 | 80513-119-01 | Gas Relief Ultimate Strength Softgels | CAPSULE, LIQUID FILLED | 2026-02-01 | M002 |
| 5 | 80513-117-12 | Gas Relief | CAPSULE, LIQUID FILLED | 2025-01-01 | M002 |
| 6 | 80513-771-03 | Antifungal | POWDER | 2025-01-01 | M005 |
| 7 | 80513-100-01 | DOCUSATE SODIUM, EXTRA STRENGTH 250 MG | CAPSULE, GELATIN COATED | 2022-09-15 | M007 |
| 8 | 80513-101-01 | DOCUSATE SODIUM, EXTRA STRENGTH 250 MG | CAPSULE, GELATIN COATED | 2023-05-25 | M007 |
| 9 | 80513-105-25 | SENNA-S | TABLET | 2024-08-28 | M007 |
| 10 | 80513-421-02 | Meclizine | TABLET, CHEWABLE | 2024-12-01 | M009 |
| 11 | 80513-427-02 | MECLIZINE | TABLET | 2025-09-01 | M009 |
| 12 | 80513-383-22 | NIGHT TIME SLEEP-AID | TABLET | 2024-08-01 | M010 |
| 13 | 80513-201-16 | Puregen Labs Allergy Relief | LIQUID | 2024-12-01 | M012 |
| 14 | 80513-230-08 | PurgenLabs Acetaminophen | LIQUID | 2024-06-01 | M012 |
| 15 | 80513-304-50 | NIGHTTIME COLD AND FLU RELIEF | CAPSULE, LIQUID FILLED | 2024-03-01 | M012 |
| 16 | 80513-301-50 | DAYTIME COLD AND FLU RELIEF SOFTGELS NON-DROWSY | CAPSULE, GELATIN COATED | 2023-04-24 | M012 |
| 17 | 80513-302-50 | NIGHTTIME COLD AND FLU RELIEF SOFTGELS MULTI-SYMPTOM | CAPSULE, GELATIN COATED | 2023-04-24 | M012 |
| 18 | 80513-303-50 | DAYTIME COLD AND FLU RELIEF | CAPSULE, LIQUID FILLED | 2024-03-01 | M012 |
| 19 | 80513-311-06 | Cough Relief | CAPSULE, LIQUID FILLED | 2025-01-01 | M012 |
| 20 | 80513-316-50 | Multi-Symptom Nighttime Cold and Flu Relief | CAPSULE, LIQUID FILLED | 2025-01-01 | M012 |
| 21 | 80513-407-09 | MUCUS RELIEF DM | TABLET | 2025-01-01 | M012 |
| 22 | 80513-789-01 | Nasal Decongestant PE | TABLET | 2025-06-01 | M012 |
| 23 | 80513-001-13 | Puregen Labs Acetaminophen | LIQUID | 2025-12-01 | M013 |
| 24 | 80513-289-03 | Adult Low Dose Aspirin | TABLET, DELAYED RELEASE | 2024-12-01 | M013 |
| 25 | 80513-287-03 | Aspirin 81mg Enteric Coated | TABLET, DELAYED RELEASE | 2025-05-01 | M013 |
| 26 | 80513-362-15 | Extra Strength Headache Relief | TABLET | 2025-07-01 | M013 |
| 27 | 80513-813-06 | PUREGEN LABS Maximum Strength Lidocaine | CREAM | 2024-04-22 | M015 |
| 28 | 80513-814-30 | PUREGEN LABS Pain Relief 4 Lidocaine | PATCH | 2024-06-03 | M017 |
标准化流程确保专论判定准确、文件齐备、标签合规,缩短整体办理周期。
提交配方表、活性成分、宣称用途及现有检测报告,进行初步合规评估。
比对21 CFR对应专论条款,确认产品归属类别及GRASE活性成分浓度范围。
指定美国代理人,完成FDA药品生产设施注册与产品列名申请。
按21 CFR 201.66制作Drug Facts标签,核对警示语、适应症与使用方法。
提供完整合规文件包,协助清关申报与上市后持续合规维护。
关于 OTC 化妆品出口美国合规的常见疑问解答。
微信号:KOL123567
添加时请备注「公司-职务-姓名」
优先安排资深法规专家 1 对 1 对接
我们已收到您的合规咨询需求
资深 FDA 法规顾问将在 1 个工作日内与您联系